Warfarin pretreatment does not lead to increased bleeding tendency during cardiac surgery.
OBJECTIVE
To study the influence of preoperative warfarin anticoagulation on postoperative blood loss and allogeneic blood requirement.


METHODS
Retrospective study with a matched control group.


METHODS
University and community hospital, single institutional.


METHODS
240 patients scheduled for cardiac surgery.


METHODS
Warfarin sodium was administered to 125 patients preoperatively to prevent thromboembolic complications of their underlying heart disease, 115 served as control. Approximately half of the patients in each group received aprotinin treatment during operation.


RESULTS
The international normalized ratio (INR) of the prothrombin time was preoperatively 2.4 (95% confidence interval [CI 0.95]: 2.3 to 2.6) in the warfarin group and 1.1 (CI 0.95: 1.0 to 1.1) in the control group (p < 0.05), and postoperatively 1.9 (CI 0.95: 1.8 to 2.1) (warfarin) and 1.5 (CI 0.95: 1.4 to 1.5) (control) (p < 0.05). The postoperative blood loss after 6 and 12 hours was 381 (CI 0.95: 329 to 434)/505 (CI 0.95: 439 to 571) mL (warfarin) compared with 472 (CI 0.95: 403 to 541)/612 (CI 0.95: 527 to 697) mL (control) (p < 0.05). This difference was blunted when the proteinase inhibitor aprotinin was used. Neither preoperative nor postoperative prothrombin time correlated with blood loss. Despite lower heparin consumption the activated coagulation time (ACT) during CPB was significantly prolonged in the warfarin group.


CONCLUSIONS
Warfarin pretreatment does not lead to increased bleeding but may even have a beneficial anticoagulant effect that may lead to better preserved postoperative hemostasis and reduced blood loss.
Dietrich
W
W
Department of Anesthesia, German Heart Center Munich.
Dilthey
G
G
Spannagl
M
M
Richter
J A
JA
D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D001803:Blood Transfusion; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D016022:Case-Control Studies; D016001:Confidence Intervals; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006488:Hemostasis, Surgical; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011292:Premedication; D011517:Prothrombin Time; D012189:Retrospective Studies; D013923:Thromboembolism / Q000517:prevention & control; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*; D014914:Whole Blood Coagulation Time
D014859:Warfarin; D006493:Heparin; D007611:Aprotinin